What the research examined
A pooled analysis of phase 3 trials assessed visceral-fat and related measurements in people with HIV and excess abdominal fat. A separate randomized study examined visceral and liver fat in a similar clinical context, describing the liver findings as preliminary.
How to interpret the findings
The populations and clinical setting are specific. A reduction in an imaging-based fat measurement does not establish every proposed long-term health benefit or justify extending results to healthy populations or different preparations.
Research literature
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
The Journal of clinical endocrinology and metabolism · 2010 · PMID 20554713 - Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
JAMA · 2014 · PMID 25038357
Links open the indexed paper records. Summaries are based on those records and their available abstracts, not a systematic review or a full-text appraisal of every study.